Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core and Main Inc (CNM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Core and Main IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Core and Main Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Core and Main Inc trades at $45.89 (market cap $8.73B), while Vertex Pharmaceuticals Incorporated trades at $525.77 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.4× Core and Main Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.

CNMVRTX
Market Cap
$8.73B$134.25B
Sector
TechnologyHealth
52-Week High
$66.98$529.65
52-Week Low
$42.37$376.62
Enterprise Value
$11.02B$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core and Main Inc

Core & Main (CNM) trades at $45.85, down 0.97% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings of $0.57 per share, beating estimates, and maintains solid fundamentals including a 23.73% ROE and 5.87% net margin. Recent news highlights institutional activity, such as California State Teachers Retirement System increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).

The outlook is positive with analyst consensus at 57% buy ratings, supported by revenue growth to $7.6B in 2026 and expanding margins. Risks include high debt levels at $2.24B long-term and competitive pressures in the tools sector. Investors should monitor execution against FY26 guidance of $7.8–$7.9B revenue.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.

The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.

Returns comparison

Trailing returns across standard periods

About Core and Main Inc

Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.

Read more on CNM

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX